Get the Stockscreener App
49.34
3.83%
1.82
After Hours:
49.34
Lb Pharmaceuticals Inc stock is traded at $49.34, with a volume of 205.86K.
It is up +3.83% in the last 24 hours and up +9.64% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$47.52
Open:
$47.47
24h Volume:
205.86K
Relative Volume:
0.66
Market Cap:
$1.59B
Revenue:
-
Net Income/Loss:
$-38.95M
P/E Ratio:
-33.21
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
+3.37%
1M Performance:
+9.64%
6M Performance:
+102.21%
1Y Performance:
+0.00%
1-Day Range:
$47.47
$49.91
1-Week Range:
$46.38
$49.93
52-Week Range:
$13.36
$50.16
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
49.34 | 1.52B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighTime to Buy? - MarketBeat
LB (LBRX) Technical Check: Climbs 1.88% to $47.10 on the Day; Level Position: the $44.74 to $49.46 Range Remains in FocusPositive Gamma - vinanet.vn
LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen - marketbeat.com
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A - Stock Titan
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook - Investing.com
Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $53 - Moomoo
LB PHARMACEUTICALS INC : STIFEL RAISES TARGET PRICE TO $53 FROM $40 - Bitget
LB PHARMACEUTICALS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $55 FROM $40 - webull.com
LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) Stock Price, News & Analysis - Kalkine
BMO Capital Markets Increases LB Pharmaceuticals (NASDAQ:LBRX) Price Target to $54.00 - MarketBeat
LB PHARMACEUTICALS INC : BMO RAISES TARGET PRICE TO $54 FROM $46 - Bitget
LBRX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Form 8K LB Pharmaceuticals Inc For: 11 August - Investing.com India
LB Pharmaceuticals Inc Stock 12‑Month Price Target Raised to $47.67, Implies 4% Upside - TradingView
LB Pharmaceuticals Submits Q2 2026 SEC Form 10-Q Reporting 32.26M Shares Outstanding - Kalkine Media
LB Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
LB Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Form 8K LB Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Q2 Loss Per Share Narrows - Yahoo Finance
LB PHARMACEUTICALS INC Q2 2026: Revenue $0 Net loss $(51.6M), EPS $(1.71) — 10-Q Summary - TradingView
Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss - marketscreener.com
LB Pharmaceuticals Reports Q2 2026 Results, Advances LB-102 Timeline and Pipeline Expansion - Quiver Quantitative
LB Pharmaceuticals reports Q2 2026 net loss of $51.6M, cash $327.8M; pivots LB-102 development - TradingView
LB Pharmaceuticals Q2 net loss widens on higher R&D costs - TradingView
LB Pharmaceuticals Inc.: Q2 Earnings Snapshot - The Daily Gazette
Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
Janus Henderson Group PLC Takes Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX Q1 2026 Earnings: Narrower Loss of -$0.67 Beats Estimates, Yet Shares Slide 5.23% - vinanet.vn
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Optimistic Estimate for LBRX Earnings - MarketBeat
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
Price to sales forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
Form 4 LB Pharmaceuticals Inc For: 3 August By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight on LB Pharmaceuticals stock - Investing.com
Piper Sandler reiterates Overweight on LB Pharmaceuticals stock By Investing.com - Investing.com Nigeria
LBRX Q1 2026 Earnings: EPS Beat by 11.8% Despite Pre-Revenue StatusEarnings Seasonality - vinanet.vn
Enterprise value to revenue forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc Revenue Breakdown – NASDAQ:LBRX - TradingView
Stempoint Capital LP Takes $1.23 Million Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals raises $150M in private placement By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Prices ~$150 Million Private Placement of Stock and Pre-Funded Warrants - TradingView
LB Pharmaceuticals Announces $150 Million Private Placement - globenewswire.com
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 8.2%What's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 1-Year HighWhat's Next? - MarketBeat
Eversept Partners LP Makes New $2.47 Million Investment in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc (LBRX) Balance Sheet - TradingKey
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LBRX|LB Pharmaceuticals Inc|Price:35.010|Chg%:+0.390 - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lb Pharmaceuticals Inc Stock (LBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
2,000,000 |
30,000,000 |
2,686,138 |
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):